Yahoo Finance EN

H.C. Wainwright Lowers PT on Soleno (SLNO), Keeps a Buy Rating

Mar 10, 2026 &03311010202631; 00:31 UTC finance.yahoo.com

Read original on finance.yahoo.com ↗

→

Neutral impact

Sentiment score: -15/100

Low impact Short-term (days)

WHAT THIS MEANS

H.C. Wainwright reduced its price target on Soleno Therapeutics (SLNO) but maintained a Buy rating, suggesting the analyst still sees upside potential despite near-term valuation concerns. This mixed signal indicates confidence in the company's long-term prospects while acknowledging current market conditions.

AI CONFIDENCE

65% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

⇅

SLNO

SLNOStock

High volatility expected

Price target reduction creates near-term selling pressure, but maintained Buy rating provides support for long-term investors

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Monitor SLNO for intraday volatility following the PT cut. Long-term investors may view this as a buying opportunity given the maintained Buy rating, while traders should watch for support levels. Consider waiting for market reaction before establishing new positions.

KEY SIGNALS

Analyst price target reduction indicates valuation resetMaintained Buy rating shows continued confidence in fundamentalsMixed signal may create short-term volatility before stabilizationTypical of biotech sector reassessment during market uncertainty

SECTORS INVOLVED

HealthcareBiotechnologyPharmaceuticals

Analysis generated on Mar 12, 2026 at 02:20 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

H.C. Wainwright Lowers PT on Soleno (SLNO), Keeps a Buy Rating

RELATED INTELLIGENCE